Aspergillosis
MONDO:0005657Aspergillosis is an infection, growth, or allergic response caused by the Aspergillus fungus. There are several different kinds of aspergillosis. One kind is allergic bronchopulmonary aspergillosis (also called ABPA), a condition where the fungus causes allergic respiratory symptoms similar to asthma, such as wheezing and coughing, but does not actually invade and destroy tissue. Another kind of aspergillosis is invasive aspergillosis. This infection usually affects people with weakened immune systems due to cancer, AIDS, leukemia, organ transplantation, chemotherapy, or other conditions or events that reduce the number of normal white blood cells. In this condition, the fungus invades and damages tissues in the body. Invasive aspergillosis most commonly affects the lungs, but can also cause infection in many other organs and can spread throughout the body (commonly affecting the kidneys and brain). Aspergilloma, a growth (fungus ball) that develops in an area of previous lung disease such as tuberculosis or lung abscess, is a third kind of aspergillosis. This type of aspergillosis is composed of a tangled mass of fungus fibers, blood clots, and white blood cells. The fungus ball gradually enlarges, destroying lung tissue in the process, but usually does not spread to other areas.
72 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Promising fungal infection treatment study halted early
Disease control TerminatedThis study tested whether adding an inhaled medication (PC945) to standard antifungal drugs could help people with a severe, hard-to-treat lung fungal infection called invasive pulmonary aspergillosis. The trial aimed to see if the combination improved survival and response by da…
Phase: PHASE3 • Sponsor: Pulmocide Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New hope against deadly molds? early trial cut short
Disease control TerminatedThis study tested a drug called fosmanogepix in 21 adults with invasive mold infections (like Aspergillus or rare molds) who had few other options. The trial was stopped early, so we have limited data on how well it works or its safety.
Phase: PHASE2 • Sponsor: Basilea Pharmaceutica • Aim: Disease control
Last updated Jun 26, 2026 17:54 UTC
-
Sticker shock: simple reminder may cut unnecessary IV antibiotic use
Knowledge-focused TerminatedThis study tested whether placing a reminder sticker on the charts of adult hospital patients receiving IV fluoroquinolone antibiotics would encourage doctors to switch them to oral pills sooner. The trial involved 168 patients at a single hospital in Thailand. Unfortunately, the…
Phase: NA • Sponsor: Mahidol University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC